Inferra AI / Company / CTVA

Corteva

CTVA · Materials

Last earnings Oct 1, 2026

Key results

EPSquarter

$1.74 billion

GAAP income and earnings per share (EPS) from continuing operations were $1.74 billion and $2.54 per share, respectively.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

AI analysis

Q3 2025 · reported Nov 4, 2025

Based on: Earnings release + parent 8-K — transcript not held

EPS · Q3 2025
$1.74B
EX-99 · Nov 4, 2025

Headline figures

MetricQ3 2025Prior qtrYear ago
EPS$1.74 billion——

EX-99 · Nov 4, 2025

Guidance · company-stated

Direction: Raised

Company outlook

“htm EX-99.1 a3q_2025xearningsxnewsxr 1 News Release Corteva Raises Full-Year Guidance on Strong Third Quarter and Year-To-Date 2025 Results YTD results reflect volume gains in both segments, demand for new technology, and outperformance on controllables Crop Protection YTD results driven by double-digit volume growth in new products and biologicals Seed YTD results reflect demand for newest hybrids and varieties, strong operational execution, and growth in out-licensing Full-year 2025 guidance3 raised due to year-to-date performance, incremental controllable lever benefits, and strength of growth platforms INDIANAPOLIS, Ind.”

Classified from the release's primary full-year outlook statement.

Next earningsNo verified date on fileNo date is estimated or imported

Capital allocation

Raw material deflation, productivity savings, and volume growth more than offset the unfavorable impact of currency, price pressure, and higher compensation and bad debt expense in SG&A.

The Company expects to repurchase approximately $1.0 billion of shares in 2025.

General educational research only — not investment advice.Every figure is as stated in the held documents; values marked “computed from stated figures” are arithmetic on those stated figures. Guidance shown is the company’s own stated guidance. No price targets, no recommendations, no consensus estimates.

Event summary

3Q 2025 Results Overview Net Sales Loss from Cont

Based on: Earnings release + parent 8-K — transcript not held

Guidance & outlook

Direction: Raised

Company outlook: “htm EX-99.1 a3q_2025xearningsxnewsxr 1 News Release Corteva Raises Full-Year Guidance on Strong Third Quarter and Year-To-Date 2025 Results YTD results reflect volume gains in both segments, demand for new technology, and outperformance on controllables Crop Protection YTD results driven by double-digit volume growth in new products and biologicals Seed YTD results reflect demand for newest hybrids and varieties, strong operational execution, and growth in out-licensing Full-year 2025 guidance3 raised due to year-to-date performance, incremental controllable lever benefits, and strength of growth platforms INDIANAPOLIS, Ind.”

Company outlook — Raised (“Raises”)
“htm EX-99.1 a3q_2025xearningsxnewsxr 1 News Release Corteva Raises Full-Year Guidance on Strong Third Quarter and Year-To-Date 2025 Results YTD results reflect volume gains in both segments, demand for new technology, and outperformance on controllables Crop Protection YTD results driven by double-digit volume growth in new products and biologicals Seed YTD results reflect demand for newest hybrids and varieties, strong operational execution, and growth in out-licensing Full-year 2025 guidance3 raised due to year-to-date performance, incremental controllable lever benefits, and strength of growth platforms INDIANAPOLIS, Ind.”

Classified from the release's primary full-year outlook statement.

Capital allocation

Raw material deflation, productivity savings, and volume growth more than offset the unfavorable impact of currency, price pressure, and higher compensation and bad debt expense in SG&A.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

The Company expects to repurchase approximately $1.0 billion of shares in 2025.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Strategy & priorities

Price/Mix was up 3% led by North America2 and EMEA2 with continued execution on the Company s price-for-value strategy for new technology offerings.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

In Crop Protection, demand for differentiated technology and productivity gains support margin expansion, while Seed continues to benefit from its strength in advanced genetics, growth in out-licensing and ongoing cost discipline.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Our planned separation in the second half of 2026 is driven by our belief that it will create long-term value, as New Corteva and SpinCo strengthen their positions as market leaders with sharper focus, tailored capital allocation strategies and increased flexibility.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Chuck Magro Chief Executive Officer Company Updates On October 1, 2025, the Company announced its plan to separate into two independent public companies: New Corteva, focused on differentiated technology solutions in crop protection, including biologicals, and SpinCo, dedicated to advanced genetics and emerging technologies including gene editing, hybrid wheat, and biofuels.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Strategic Rationale Distinct Market Opportunities: The separation enables tailored innovation, operational design, and go-to-market strategies for each company.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Risks & headwinds

As it pertains to ongoing tariff negotiations around the world, we are not expecting a material net impact on our full-year 2025 results given policies in place today.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

(NYSE: CTVA) is a global pure-play agriculture company that combines industry-leading innovation, high-touch customer engagement and operational execution to profitably deliver solutions for the world s most pressing agriculture challenges.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

All statements that address expectations or projections about the future, including statements about Corteva s financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; sustainability targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond the company's control.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business.

SEC original ↗Corteva — Earnings release (8-K exhibit)EX-99Nov 4, 2025

Competitors

Competitors & peers

Same GICS sector — classification peers, not declared competitors

Documents

Filings

70 documents

Earnings releases

40 documents

Presentations

0 documents

No presentations for Corteva are held in this edition of the library.

Transcripts

0 documents

No transcripts for Corteva are held in this edition of the library.

Mentioned by

8 companies

Other tracked companies whose held documents mention Corteva by name or ticker. A mention is counted once per document, from the document text the library holds.

See also the earnings calendar for every tracked company’s next earnings date.